The ACR endorses quality measures related to the care of rheumatic disease. Sometimes these measures have been developed and tested by the ACR, but at times the ACR endorses or promotes the use of measures that have been developed and tested by others. The ACR’s ultimate goal is for providers of rheumatology care to have one parsimonious set of meaningful quality measures to use in external quality reporting, improvement, and performance programs.
The ACR has most recently developed and tested the following RA measures (2014), which are being used in the ACR’s RISE registry:
Learn more in the ACR paper, Development of the American College of Rheumatology’s Rheumatoid Arthritis Electronic Clinical Quality Measures, published November 2016.
RA Measure Development Project
The ACR previously participated in an RA measure development project (2008) that resulted in the following measures, all of which are included in the CMS Physician Quality Reporting System (PQRS) RA measure group and are used in the ACR’s RISE registry:
A sixth measure, developed by the National Committee on Quality Assurance (NCQA), is also part of the PQRS RA measure group:
6. RA – DMARD therapy: Percentage of patients 18 years and older with a diagnosis of rheumatoid arthritis who were prescribed, dispensed or administered at least one ambulatory prescription for a DMARD
The ACR has developed the following gout measures, which are being used in the ACR’s RISE registry and tested in U.S. clinical practices:
Learn more in the ACR paper, Development of the American College of Rheumatology Electronic Clinical Quality Measures for Gout, published April 2018.
Request detailed specifications for any of these measures: